Serum homocysteine levels are affected by renal function during a 3-year period of minodronate therapy in female osteoporotic patients
- 67 Downloads
Serum homocysteine is a possible marker to indicate bone quality. However, it is not clear whether changes are seen in serum homocysteine levels with long-term bisphosphonate therapy. We aimed to investigate the factors affecting serum homocysteine levels during a 3-year period of monthly minodronate therapy in osteoporotic women, and to examine if the serum homocysteine levels could reflect some aspects of bone metabolism. The study included 43 patients (age 72.3 ± 7.0 years) undergoing treatment for osteoporosis for the first time (New group) and 35 patients (age 74.4 ± 8.2 years) who switched from alendronate or risedronate to minodronate (Switch group). Minodronate (50 mg/every 4 weeks) was administered for 36 months. Lumbar, femoral neck, and total hip bone mineral densities (BMD), and serum homocysteine levels were monitored at baseline and after 9, 18, 27, and 36 months of treatment. Lumbar BMD increased significantly in both groups (New group 11.4%, Switch group 6.2%). However, femoral neck and total hip BMDs increased only in the New group (femoral neck 3.6%, total hip 4.1%). Serum homocysteine levels increased significantly at 18 and 27 months in all subjects. Multiple linear regression analysis revealed that changes in homocysteine levels during 18, 27, and 36 months significantly correlated with changes in creatinine clearance during the same corresponding periods (18 months: B = − 0.472, p = 0.003; 27 months: B = − 0.375, p = 0.021; 36 months: B = − 0.445, p = 0.012). Thus, serum homocysteine levels possibly reflect renal function instead of bone metabolism during minodronate therapy.
KeywordsBisphosphonate Bone mineral density Homocysteine Minodronate Osteoporosis
The authors would like to thank Yoshiaki Ito, Yasuyuki Takabayashi, and Yasuhide Suzuki, who are laboratory technicians at Enshu Hospital, for their assistance with blood sample preparation.
Compliance with ethical standards
Conflict of interest
The authors report no conflicts of interest. The authors are responsible for the content and writing of the paper.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
- 10.Enneman AW, Swart KMA, Zillikens MC, van Dijk SC, van Wijingaarden PJ, Brouwer-Brolsma EM, Dhonukshe-Rutten RAM, Hofman A, Rivadeneira F, van der Cammen TJM, Lips P, de Groot CPGM, Uitterlinden AG, van Meurs JBJ, van Scoor NM, van der Velde N (2014) The association between plasma homocysteine levels and bone quality and bone mineral density parameters in older persons. Bone 63:141–146CrossRefPubMedGoogle Scholar
- 15.Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ (2001) Structure–activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonate. J Pharmacol Exp Ther 296:235–242PubMedGoogle Scholar
- 17.Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H (2001) Osteoporosis diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337CrossRefPubMedGoogle Scholar
- 20.Kimoto A, Tanaka M, Nozaki Mori M, Fukushima S, Mori H, Ahioya T, Nakamura T (2013) Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment. Bone 55:189–197CrossRefPubMedGoogle Scholar
- 23.Jin A, Cobb J, HansenU Bhattacharya R, Reinhard C, Vo N, Atwood R, Li J, Karunaratne A, Wiles C, Abel R (2017) The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density. Bone Joint Res 6:602–609. https://doi.org/10.1302/2046-3758.610.BJR-2016-0321.R1 CrossRefPubMedCentralPubMedGoogle Scholar
- 24.Ma S, Goh EL, Jin A, Bhattacharya R, Boughton OR, Patel B, Karunaratne A, Vo NT, Atwood R, Cobb JP, HansenU Abel RL (2017) Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties. Sci Rep 7:43399. https://doi.org/10.1038/srep43399 CrossRefPubMedCentralPubMedGoogle Scholar
- 32.Yamada C, Fujimoto S, Ikeda K, Nomura Y, Matsubara A, Kanno M, Shide K, Tanaka K, Imai E, Fukuwatari T, Shibata K, Inagaki N (2011) Relationship of homocysteine and homocysteine-related vitamins to bone mineral density in Japanese patients with type 2 diabetes. J Diabetes Investig 2:233–239CrossRefPubMedGoogle Scholar